Retina

Dr Nadia K. Waheed reviews the latest updates on the FOCUS trial, evaluating AAV-based viral vector GT005 for the treatment of geographic atrophy.

Dr David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.

A once-daily oral drug targets inflammatory processes and thus far has been found to be well tolerated in a Phase 2 safety trial.

Dr Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DMO resolution.

A new home telemedicine system generates valuable data on disease and the dynamics of fluid exudation.

A team of investigators are working on a simple test that may someday identify those who can stop therapy.

Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

The improvement became evident during an average time of 6 months.

Dr Firas Rahhal discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Ophthalmologists gather to discuss neovascular and exudative diseases of the eye and the revolutionary therapies on the horizon.

A University of California Davis, United States, study shows that small serving of the fruit increased protective pigments in the eye.

The difference between retina’s biological age and person’s real age linked to heightened death risk, with a team of Australian investigators finding that evidence suggests the microvasculature in the retina may be a reliable indicator of the overall health of the body’s circulatory system and the brain.

According to Haag-Streit UK, the iScan80 is a high-speed OCT system ideal for practices seeking an affordable and versatile OCT system.

Recent literature review reveals dearth of data, highlights need for more research.

Dr Ted Leng discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.

Eyes with larger fluctuations in central subfield thickness (CST) had worse VA compared with eyes with the fewest CST fluctuations in both protocols, according to investigators.

Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.

Current options, challenges in developing novel therapies.

According to investigators, the virtual reality option could overcome hurdles associated with reliance on a physical course.

Assessment of renal function could help explain the treatment response for patients with diabetic macular oedema.

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

Teleretinal screening programs prove a cost-effective option in preventing blindness related to diabetic retinopathy.

Imaging study revealed specific retinal and choroidal changes associated with Parkinson's disease.

Dr Jay Duker discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Underlying autoimmune disease alters uveitis therapy.

Surgical options facilitate increased durability for patients with retinal degeneration.

Confronting issues unique to aging may lead to better outcomes.

In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Mark Wieland noted that the port delivery system with ranibizumab provides drug delivery over an extended period.

Dr Sunir J. Garg speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.